Media stories about Insys Therapeutics (NASDAQ:INSY) have trended somewhat negative this week, Accern Sentiment reports. Accern identifies negative and positive news coverage by analyzing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Insys Therapeutics earned a media sentiment score of -0.02 on Accern’s scale. Accern also gave news coverage about the specialty pharmaceutical company an impact score of 45.4681870244904 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near future.

These are some of the news articles that may have effected Accern Sentiment’s scoring:

Shares of Insys Therapeutics (NASDAQ:INSY) remained flat at $5.74 during midday trading on Monday. 3 shares of the company were exchanged. The firm’s 50-day moving average is $8.35 and its 200 day moving average is $10.61. The firm’s market capitalization is $417.28 million. Insys Therapeutics has a 52-week low of $5.18 and a 52-week high of $15.06.

Insys Therapeutics (NASDAQ:INSY) last announced its earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported $0.03 EPS for the quarter, beating the consensus estimate of ($0.09) by $0.12. Insys Therapeutics had a negative return on equity of 3.02% and a negative net margin of 9.63%. The company had revenue of $42.60 million for the quarter, compared to analyst estimates of $36.90 million. During the same quarter in the prior year, the company earned $0.13 EPS. The firm’s revenue for the quarter was down 38.4% compared to the same quarter last year. On average, analysts predict that Insys Therapeutics will post ($0.33) EPS for the current year.

A number of equities research analysts have recently commented on the company. BidaskClub raised Insys Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, July 8th. Royal Bank Of Canada dropped their price target on Insys Therapeutics from $16.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, August 4th. Zacks Investment Research lowered Insys Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, August 9th. Piper Jaffray Companies set a $10.00 price target on Insys Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings Inc. reaffirmed a “hold” rating on shares of Insys Therapeutics in a research report on Tuesday, July 4th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus price target of $10.13.

COPYRIGHT VIOLATION NOTICE: “Insys Therapeutics (INSY) Earning Somewhat Critical Press Coverage, Report Finds” was posted by TheOlympiaReport and is owned by of TheOlympiaReport. If you are reading this article on another website, it was illegally copied and republished in violation of international trademark and copyright laws. The original version of this article can be read at

In other news, major shareholder John N. Kapoor Trust Dated Sept purchased 17,500 shares of the business’s stock in a transaction on Friday, August 11th. The shares were acquired at an average price of $8.93 per share, for a total transaction of $156,275.00. Following the completion of the acquisition, the insider now owns 31,982 shares in the company, valued at $285,599.26. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Saeed Motahari purchased 5,500 shares of the business’s stock in a transaction on Thursday, August 10th. The stock was purchased at an average price of $8.92 per share, for a total transaction of $49,060.00. Following the acquisition, the chief executive officer now owns 15,400 shares of the company’s stock, valued at approximately $137,368. The disclosure for this purchase can be found here. 67.90% of the stock is currently owned by corporate insiders.

Insys Therapeutics Company Profile

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Insider Buying and Selling by Quarter for Insys Therapeutics (NASDAQ:INSY)

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.